claude-stocks
FX:1$ = 0.920
privat / nicomang
← Watchlist

NVO

Novo NordiskHOLD
pharma-glp1 · framework=dcf · peers=LLY, SNY, AZN, RHHBY

⚡ Narrativ-Shift

Magnitude: +16.5%

FV revised from $39.50 to $46.00 driven by FDA-approved oral Wegovy pill (Dec 2025) launch at $149/month opening injection-averse patient cohort. Oral semaglutide reaches 50,000 Rx/week pace, providing patent-cliff buffer.

Preis
$42.22
+4.8%
vs 30.04.2026
Fair Value (blended)
$46.00
+21.8%
vs 30.04.2026
Upside
+8.9%
+243.2%
Confidence 0.57
Snapshot
01.05.2026
heute

Chart & Einstieg

Lade Chart …

Forward Fair Value · Calculator

%
Claude: -7.30 %
bps/Jahr
Claude: -80 bps/Jahr
x
Claude: 14.0 x
%
Claude: 12.00 %
JahrClaude FVDeine FVΔ FVRevenue (Deine)Margin (Deine)Upside ClaudeUpside Deine
Ende 2026$0.00$0.00$42B+45.0%-100.0%-100.0%
Ende 2027$0.00$0.00$46B+47.0%-100.0%-100.0%
Ende 2028$0.00$0.00$51B+49.0%-100.0%-100.0%

Historie (5 Jahre)

Lade Historie …

Begründung

Novo Nordisk's FV is revised upward from $39.50 to $46.00 (+16.5%) following two structural positives: (1) FDA approval of oral Wegovy pill (December 2025) and commercial launch at $149/month, which opens a massive injection-averse patient segment (~50% of obesity patients who refuse injections) and partially hedges the 2031/32 semaglutide patent cliff; (2) pediatric Type 2 diabetes oral semaglutide data, expanding the addressable population. Q1 2026 earnings on May 6 carry downside risk from MFN pricing dynamics and US channel inventory destocking, with guidance of -5% to -13% CER for FY2026. At $42.22 and 11.7x P/E, NVO is the cheapest large-cap pharma relative to FCF yield (~4.6%), providing margin of safety. Blended FV $46 uses a pharma DCF ($43, conservative on 2026 decline) and 10.5x EBITDA multiple ($49).

These · aktualisiert 01.05.2026

Bull Case

Novo Nordisk has navigated a major de-rating (>50% from peak) and is now attractively valued at 11.7x P/E — the cheapest large-cap pharma relative to earnings quality. The December 2025 FDA approval of oral Wegovy (first-ever oral GLP-1 for obesity) at $149/month is a structural game-changer: it opens the ~50% of patients who refuse injections and creates a new patient funnel at dramatically lower price points. With 50,000 Rx/week within weeks of launch at 70,000+ pharmacies, the adoption curve is steeper than any prior GLP-1 launch. The 2026 guidance decline (-5% to -13% CER) represents a trough year; FY2027 begins the recovery driven by oral semaglutide scale, Amycretin/Zenagamtide Phase 3, and ex-US GLP-1 penetration still at early innings.

Bear Case

CagriSema's clinical miss removed Novo's most important next-gen asset protecting against the 2031/32 semaglutide patent cliff. Without a clearly superior successor molecule to tirzepatide, the post-cliff revenue decline could be steeper than current models assume. The January 2027 Wegovy/Ozempic 50% list price cut will compress 2027 US revenue by $5-8B, making the year-1 oral semaglutide revenue meaningful but insufficient to fully offset the pricing headwind. Eli Lilly's orforglipron (oral, once-daily, no food restrictions) in Phase 3 could erode oral Wegovy market share from 2027.

Catalysts

May 6, 2026: Q1 2026 earnings — first detailed oral Wegovy prescription data and US channel inventory update. H2 2026: Amycretin/Zenagamtide Phase 3 readouts — critical for patent-cliff hedge. January 2027: 50% Wegovy/Ozempic list price cut implementation — market reaction defines 2027 re-rating direction. Any positive CagriSema formulation rescue data would be strongly positive.

Risks

1) Oral Wegovy vs orforglipron competition: Lilly's oral GLP-1 in Phase 3 lacks the food-timing restriction of early semaglutide formulations — if approved with superior convenience, it could materially slow oral Wegovy adoption from 2027. 2) MFN pricing 2027: beyond the 50% list price cut, further executive order MFN application could reduce net pricing by another 20-30%, compressing the terminal value in the DCF. 3) Pipeline: Amycretin failure would leave Novo without a credible next-generation obesity molecule, making the post-2031 cliff the defining bear case.

Snapshot-History

DatumPreisMarket CapP/ERev TTMRev GrowthEBITDA-Marge
01.05.2026$42.22$187.5B11.7$45.3B+6.4%+48.4%
30.04.2026$40.29$179.1B11.2$45.3B+6.4%+48.4%

News